Tag Archive for: EQT life sciences

Weekly Roundup: Events, events & more events

/in

Hansa Biopharma’s ConfIdeS Phase 3 abstract selected for ‘What’s Hot, What’s New’ plenary at ATC 2026  Hansa Biopharma AB, announced on Thursday that the ConfIdeS Phase 3 abstract titled “Superior 1-year eGFR Among Highly Sensitized Patients Desensitized with Imlifidase Compared to Control” had been selected to be highlighted at the closing plenary session “What’s Hot, What’s New” at the American Transplant Congress (ATC) 2026, which took place in Boston on June […]

Read more

ViCentra Raises $85M to Scale Manufacturing and Accelerate Market Penetration of Kaleido Insulin Patch Pump

/in

Led by new investor Innovation Industries, with matching contributions from existing investors, Partners in Equity and Invest-NL, the $85M round also drew support from EQT Life Sciences and Health Innovations, demonstrating strong confidence in ViCentra’s next phase of growth Fresh capital fuels scale-up, regulatory pathway, and commercialization of Kaleido 2, the world’s smallest, lightest, and […]

Read more

SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines

/in

Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investors Proceeds will support clinical development of lead program SB-007 in Stargardt disease Funding will also advance a broader pipeline of genetic medicines targeting indications in ophthalmology, neurology, and other undisclosed therapeutic areas […]

Read more

MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus

/in

New investment from EQT Life Sciences and OrbiMed with participation from existing investors MinervaX will hold financial reserves of more than €125 million, following the financing The financing supports the Company’s efforts to commence a Phase III clinical trial of its Maternal Vaccine against Group B Streptococcus Copenhagen, Denmark, 11 October 2023 – MinervaX ApS, a […]

Read more

Ariceum Therapeutics Launches with €25M Series A

/in

Find out what sets Ariceum Therapetutics apart within the radiopharmaceutical arena in this insightful interview with its CEO Manfred Rüdiger and Tyler Patchen of Endpoint News

Read more
© Optimum Strategic Communications.